DUBLIN, March 3, 2017 /PRNewswire/ -- Allergan plc,
(NYSE: AGN), a leading global pharmaceutical company, announced
today that it will present 21 Allergan-supported abstracts, a
record high for the brand, at the 2017 Annual American Academy of
Dermatology (AAD) meeting in Orlando,
Florida from March 3-7,
2017.
The scheduled times (noted in local Eastern Time) of the 21
Allergan presentations, presentation titles, locations and authors
are as follows:
Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe
Forehead Lines in Subjects With Upper Facial Lines
- Date and Time: Friday, March
3, 1:35-1:40 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Koen De Boulle, Philip
Werschler, Michael H. Gold,
Suzanne Bruce, Gerhard Sattler, Patricia Ogilvie, Cheri
Mao, Domenico Vitarella,
Xiaofang Lei, Bhushan Hardas
Efficacy and Safety of OnabotulinumtoxinA for Treatment of
Moderate to Severe Forehead Lines
- Date and Time: Friday, March
3, 1:40-1:45 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Steve Fagien, Joel L.
Cohen, William Coleman,
Gary Monheit, Jean Carruthers, Cheri
Mao, Domenico Vitarella,
Xiaofang Lei, Bhushan Hardas
OnabotulinumtoxinA (BOTOX®) Displays Superior
Activity to IncobotulinumtoxinA Drug Product (XEOMIN®)
in Multiple In Vitro and In Vivo Assays
- Date and Time: Friday, March
3, 2:45-2:50 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: David Canty,
Linh Le, Joanne Wang, Greg
Nicholson, Amy
Brideau-Andersen, Lance
Steward, Birgitte Jacky, Ron
Broide, Mark Washburn,
David Rupp
Safety and Tolerability of OnabotulinumtoxinA in the Treatment
of Facial Lines: Statistical Meta-analysis of Pooled Data From
Global Registration Studies of Treatment of Crow's Feet Lines and
Glabellar Lines in More Than 3900 Participants
- Date and Time: Friday, March
3, 3:40-3:45 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Jean Carruthers,
Mitchell F. Brin, Koen De Boulle,
Steven Liew, Alastair Carruthers, Alexander Rivkin, Yan
Wu, Irina Yushmanova, Terry I.
Boodhoo, Kathy Zhuang,
Conor J. Gallagher, Elisabeth Lee
A comparison of self-reported signs of facial aging among women
in Australia vs. those in
the United States, United Kingdom & Canada
- Date and Time: Friday, March
3, 11:45-11:50 AM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Greg J. Goodman,
Katherine Armour, Julia Kolodziejczyk, Conor J. Gallagher
Characterization of the In Vivo Pharmacology of Oxymetazoline
and Brimonidine Using a Mouse Model of UV-Induced Erythema
- Date and Time: Friday, March
3, 1:10-1:15 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Edward Hsia,
Mingting Tian, Daniel Gil
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for
Treatment of Facial Erythema Associated With Rosacea: Findings From
Two Phase 3, Pivotal Trials
- Date and Time: Friday, March
3, 1:45-1:50 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Linda
Stein-Gold, Leon H. Kircik,
Zoe Diane Draelos, Philip Werschler, Janet
DuBois, Edward Lain,
Leslie Baumann, David J. Goldberg, Joely
Kaufman, Emil A. Tanghetti,
Emily Weng, David R. Berk, Gurpreet
Ahluwalia
Patient-Rated Satisfaction Assessment for Rosacea Facial Redness
(SAT-RFR): Results of Two Phase 3 Pivotal Trials of Oxymetazoline
Cream 1% vs Vehicle
- Date and Time: Friday, March
3, 9:00-9:05 AM
- Location: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Ilia L. Ferrusi,
Gurpreet Ahluwalia, David A. Andrae
Patient-Rated Symptom Assessment for Rosacea Facial Redness
(SA-RFR): Results of Two Phase 3 Pivotal Trials of Oxymetazoline
Cream 1% vs Vehicle
- Date and Time: Friday, March
3, 9:05-9:10 AM
- Location: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Ilia L. Ferrusi,
Gurpreet Ahluwalia, David A. Andrae
Development and Validation of the Satisfaction Assessment for
Rosacea Facial Redness (SAT-RFR)
- Date and Time: Friday, March
3, 1:25-1:30 PM
- Room: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Ilia L. Ferrusi,
Gurpreet Ahluwalia, David A. Andrae
Development and Validation of the Symptom Assessment for Rosacea
Facial Redness (SA-RFR)
- Date and Time: Friday, March
3, 1:30-1:35 PM
- Location: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Ilia L. Ferrusi,
Gurpreet Ahluwalia, David A. Andrae
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the
Treatment of Facial Erythema Associated With Rosacea: Findings From
1 of 2 Pivotal Trials
- Date and Time: Friday, March
3, 2:20-2:25 PM
- Location: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Leon H. Kircik,
Janet DuBois, Zoe Diane Draelos, Philip Werschler, Kimberly Grande, Fran E.
Cook-Bolden, David R. Berk,
Gurpreet Ahluwalia
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the
Treatment of Facial Erythema Associated With Rosacea: Findings From
the Second of 2 Pivotal Trials
- Date and Time: Friday, March
3, 2:25-2:30 PM
- Location: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Leslie Baumann,
David J. Goldberg, Linda Stein-Gold, Emil
A. Tanghetti, Ted Lain,
Joely Kaufman, David R. Berk, Gurpreet
Ahluwalia
Long-term Safety and Efficacy of Topical Oxymetazoline Cream
1.0% for Treatment of Persistent Facial Erythema Associated With
Rosacea
- Date and Time: Friday, March
3, 4:55-5:00 PM
- Location: E-Poster, Clinical Dermatology & Other
Cutaneous Disorders Section
- Authors: Zoe Diana
Draelos, Michael H. Gold,
Robert A. Weiss, Leslie Baumann, Steven
K. Grekin, Deanne Mraz
Robinson, Steven E. Kempers,
David R. Berk, Gurpreet Ahluwalia
Efficacy and Safety of Oral Sarecycline for the Treatment of
Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2,
Dose-Ranging Trial
- Date and Time: Friday, March
3, 9:00-9:05 AM
- Location: E-Poster, Acne Section
- Authors: James J. Leyden, Vilma Sniukiene, David R. Berk, Alexandre Kaoukhov
Cosmetic Efficacy of a Comprehensive Serum for Facial
Hyperpigmentation in Multiple Ethnic Populations
- Date and Time: Friday, March
3, 1:20-1:25 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Elizabeth T.
Makino, Priscilla Tan,
Rahul C. Mehta
Efficacy of a Comprehensive Serum in Japanese Subjects with
Moderate to Severe Facial Hyperpigmentation
- Date and Time: Friday, March
3, 1:50-1:55 PM
- Location: E-Poster, Aesthetic Dermatology
- Authors: Elizabeth T. Makino, Priscilla Tan, Rahul C.
Mehta
Efficacy of a Comprehensive Serum in Thai Subjects with Moderate
to Severe Facial Hyperpigmentation
- Date and Time: Friday, March 3,1:55-2:00 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Elizabeth T.
Makino, Priscilla Tan,
Rahul C. Mehta
Rejuvenation in neck appearance from topical treatment with
physiologically-balanced growth factors, antioxidants and sunscreen
actives
- Date and Time: Friday, March
3, 3:25-3:30 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Lisa T.
Goberdhan, Elizabeth T.
Makino, Rahul C. Mehta
Social Perceptions Before and After Treatment With ATX-101
(Deoxycholic Acid Injection) for Reduction of Submental Fat
- Date and Time: Friday, March
3, 4:05-4:10 PM
- Location: E-Poster, Aesthetic Dermatology Section
- Authors: Shannon
Humphrey, Steven H. Dayan,
Sachin M. Shridharani, Leslie Baumann, Conor J.
Gallagher
Pan-facial Aesthetic Treatment Positively and Significantly
Impacts Social Perception
- Date and Time: Saturday, March
4th from 1:00-3:00 PM
- Location: Late-Breaking Research Forum: Procedural
Dermatology, Room W304C
- Authors: Steven H. Dayan,
Alexander Rivkin, Jonathan M. Sykes, Craig
F. Teller, Susan H. Weinkle,
Garrett T. Shumate, Conor J. Gallagher
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing, manufacturing and
commercializing branded pharmaceuticals, devices and biologic
products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we
build bridges, power ideas, act fast and drive results for our
customers and patients around the world by always doing what is
right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2016 (certain of such
periodic public filings having been filed under the "Actavis plc"
name). Except as expressly required by law, Allergan disclaims any
intent or obligation to update these forward-looking
statements.
© 2017 Allergan. All rights reserved. All trademarks are the
property of their respective owners.
CONTACTS:
Investors:
Lisa
DeFrancesco
(862)
261-7152
Karina Calzadilla
(862) 261-7328
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-presents-data-from-21-abstracts-at-the-2017-american-academy-of-dermatology-meeting-in-orlando-fl-300417911.html
SOURCE Allergan plc